Anzeige
Meldung des Tages: Ein unabhängiger Analyst sieht bei dieser Goldaktie über +200 % Kurspotenzial

Palatin Technologies Aktie News

Aktie
WKN:  A41E9H ISIN:  US6960776010 US-Symbol:  PTN Branche:  Biotechnologie Land:  USA
17,55 $
+0,624 $
+3,69%
15,132 € 16.01.26
Depot/Watchlist
Marktkapitalisierung *
331,16 Mio. €
Streubesitz
88,79%
KGV
-
Index-Zuordnung
-

Palatin Technologies News

06.11.25 - PR Newswire
Palatin Presents Data at ObesityWeek® 2025 Highlighting Promise of Melanocortin-Based Therapies for Obesity
Palatin Presents Data at ObesityWeek® 2025 Highlighting Promise of Melanocortin-​Based Therapies for Obesity PR Newswire
06.11.25 - PR Newswire
Palatin Technologies Announces Pricing of Upsized $15.8 Million Public Offering
Palatin Technologies Announces Pricing of Upsized $15.8 Million Public Offering PR Newswire
22.09.25 - PR Newswire
Palatin Earns €5.5 Million ($6.5 Million) Milestone Payment in Retinal Disease Collaboration with Boehringer Ingelheim
Palatin Earns €5.5 Million ($6.5 Million) Milestone Payment in Retinal Disease Collaboration with Boehringer Ingelheim PR Newswire
08.08.25 - PR Newswire
Palatin Announces 1-for-50 Reverse Stock Split
Palatin Announces 1-for-50 Reverse Stock Split PR Newswire
15.07.25 - PR Newswire
Palatin Announces Positive Preclinical Efficacy Data for Oral MC4R Agonist PL7737 in Animal Model of Obesity
Palatin Announces Positive Preclinical Efficacy Data for Oral MC4R Agonist PL7737 in Animal Model of Obesity PR Newswire
14.05.25 - PR Newswire
Palatin Reports Fiscal Year 2025 Third Quarter Results and Business Update
Palatin Reports Fiscal Year 2025 Third Quarter Results and Business Update PR Newswire
09.05.25 - PR Newswire
Palatin Presents Promising Preclinical Data on Melanocortin Agonists for Retinopathy at ARVO 2025
Palatin Presents Promising Preclinical Data on Melanocortin Agonists for Retinopathy at ARVO 2025 PR Newswire
08.05.25 - PR Newswire
Palatin Technologies Announces Closing of Reduced Public Offering
Palatin Technologies Announces Closing of Reduced Public Offering PR Newswire
08.05.25 - PR Newswire
Palatin Presents Breakthrough Symptom Resolution Data from Phase 3 PL9643 MELODY-1 Clinical Trial in Dry Eye Disease at ARVO 2025
Palatin Presents Breakthrough Symptom Resolution Data from Phase 3 PL9643 MELODY-1 Clinical Trial in Dry Eye Disease at ARVO 2025 PR Newswire
07.05.25 - PR Newswire
Palatin Technologies Announces Transition to OTC Pink Following NYSE American Delisting Notice
Palatin Technologies Announces Transition to OTC Pink Following NYSE American Delisting Notice PR Newswire
07.05.25 - PR Newswire
Palatin Expects $11.5 Million Financing to Cure NYSE American Delisting Notice
Palatin Expects $11.5 Million Financing to Cure NYSE American Delisting Notice PR Newswire
07.05.25 - PR Newswire
Palatin Technologies Announces Pricing of up to $23 Million Public Offering
Palatin Technologies Announces Pricing of up to $23 Million Public Offering PR Newswire
05.05.25 - PR Newswire
Palatin Presents Promising Preclinical Data for Melanocortin Agonist PL9588 at ARVO 2025, Highlighting a Dual-Action Glaucoma Therapy
Palatin Presents Promising Preclinical Data for Melanocortin Agonist PL9588 at ARVO 2025, Highlighting a Dual-​Action Glaucoma Therapy PR Newswire
29.04.25 - PR Newswire
Palatin Announces Breakthrough Symptom Resolution in Updated Analyses from Phase 3 PL9643 MELODY-1 Clinical Trial in Dry Eye Disease
Palatin Announces Breakthrough Symptom Resolution in Updated Analyses from Phase 3 PL9643 MELODY-1 Clinical Trial in Dry Eye Disease PR Newswire
17.04.25 - PR Newswire
Palatin Reports Positive Appetite Suppression Results From Phase 2 Obesity Study of MC4R Agonist Bremelanotide and Tirzepatide
Palatin Reports Positive Appetite Suppression Results From Phase 2 Obesity Study of MC4R Agonist Bremelanotide and Tirzepatide PR Newswire
14.04.25 - PR Newswire
Palatin Appeals NYSE American Notice of Delisting
Palatin Appeals NYSE American Notice of Delisting PR Newswire
10.04.25 - PR Newswire
Palatin Technologies, Inc. Announces Receipt of NYSE American Notice of Delisting and Intention to Appeal
Palatin Technologies, Inc. Announces Receipt of NYSE American Notice of Delisting and Intention to Appeal PR Newswire
31.03.25 - PR Newswire
Palatin Announces MC4R Agonist Bremelanotide Co-Administered with GLP-1/GIP Tirzepatide Meets Primary Endpoint in Phase 2 Obesity Study
Palatin Announces MC4R Agonist Bremelanotide Co-​Administered with GLP-1/GIP Tirzepatide Meets Primary Endpoint in Phase 2 Obesity Study PR Newswire
28.03.25 - PR Newswire
Palatin Announces Positive Topline Results from Phase 2 Ulcerative Colitis (UC) Study of Oral Melanocortin-1 Receptor Agonist PL8177
Palatin Announces Positive Topline Results from Phase 2 Ulcerative Colitis (UC) Study of Oral Melanocortin-1 Receptor Agonist PL8177 PR Newswire
25.03.25 - PR Newswire
Palatin's Oral MC4R Agonist PL7737 Receives FDA Orphan Drug Designation for Obesity Due to Leptin Receptor Deficiency
Palatin's Oral MC4R Agonist PL7737 Receives FDA Orphan Drug Designation for Obesity Due to Leptin Receptor Deficiency PR Newswire

Newssuche

Videos

newspaper
15.01.26 -0,78%
Technical Trading: Gold Long Chance
Gold Long Typ: Turbo Open End WKN: VC5S7W Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »